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Patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) show varying
degrees of response to intravenous immunoglobulin (IVIg) therapy. This randomised phase III
study in patients with CIDP (ProCID trial) will compare the efficacy and safety of 3 different
doses (0.5, 1.0, and 2.0 g/kg) of IVIg 10% (panzyga) administered every 3 weeks for 24 weeks.
The primary efficacy endpoint is the rate of treatment response, defined as a decrease in
adjusted inflammatory neuropathy cause and treatment disability score of ≥1 point, in the IVIg
1.0 g/kg arm at week 24. Patients with definite or probable CIDP according to European Federa-
tion of Neurological Sciences/Peripheral Nerve Society criteria with IVIg or corticosteroid
dependency and active disease are eligible. All potentially eligible patients will undergo IVIg or
corticosteroid dose reduction (washout phase) over ≤12 weeks or until deterioration of CIDP
(active disease). Patients with deterioration during the washout phase will be randomised to
receive study treatment during a dose-evaluation phase starting with a loading dose of IVIg
2.0 g/kg followed by maintenance treatment with IVIg 0.5, 1.0, or 2.0 g/kg every 3 weeks. Res-
cue medication (2 doses of IVIg 2.0 g/kg given 3 weeks apart) will be administered to patients in
the IVIg 0.5 and 1.0 g/kg groups who deteriorate after week 3 and before week 18 or who do
not improve at week 6. Safety, tolerability and quality of life will be assessed. The ProCID study
will provide new information on the best maintenance dose of IVIg for patients with CIDP.
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1 | INTRODUCTION
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is
an acquired peripheral neuropathy, for which first-line therapy options
include intravenous immunoglobulin (IVIg), corticosteroids, and plasma
exchange.1 The degree of treatment response to immunoglobulin
differs between patients with CIDP, and the time to and duration of
maximum effect can vary from weeks to months.2 In the IVIg in CIDP
Efficacy (ICE) study of 117 patients with CIDP, maintenance treat-
ment with IVIg 1 g/kg every 3 weeks over 24 weeks was shown to be
effective3; however, the European Federation of Neurological Sci-
ences (EFNS)/Peripheral Nerve Society (PNS) 2010 guidelines
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recommend that the appropriate IVIg maintenance dose and fre-
quency needs to be individualised based on the patient's treatment
response, typically at 0.4 to 1.2 g/kg every 2 to 6 weeks.1
In almost all of the previous clinical studies of IVIg in patients with
CIDP, only one dose of IVIg was assessed.3–11 The efficacy and safety of
different induction doses of IVIg (0.05, 0.2, or 0.4 g/kg/d for 5 days) has
been evaluated head-to-head in only one non-placebo-controlled study
of Japanese patients with CIDP (n = 40) or multi-focal motor neuropathy
(n = 20), in which dose-dependent improvements in electrophysiology
and clinical disease at 5 weeks were observed in all patients.12 The Poly-
neuropathy and Treatment with Hizentra (PATH) study, which investi-
gated 2 different maintenance doses of weekly subcutaneous
immunoglobulin (SCIg) 0.2 or 0.4 g/kg in 172 patients with CIDP, showed
that both doses of SCIg had significantly superior efficacy to placebo.13,14
The ProCID study is a randomised, multi-centre, phase III trial of IVIg
in patients with CIDP that will compare the efficacy and safety of 3 differ-
ent maintenance doses (0.5, 1.0, and 2.0 g/kg) of IVIg (panzyga) adminis-
tered every 3 weeks over 24 weeks, following an induction dose of 2 g/
kg. Data from the ProCID study will provide important new information
on the best maintenance dose of IVIg to use when treating patients with
CIDP. Here, we report the design and protocol of the ProCID study.
2 | MATERIALS AND METHODS
2.1 | Study design
The ProCID study is a prospective, randomised, double-blind, parallel-
group, multi-centre, phase III trial. An overview of the study design is
shown in Figure 1. The trial started in May 2017 and is expected to be
completed by the end of 2019, corresponding to a total study duration
of 30 months. The study will be conducted according to the ethical
principles of the Declaration of Helsinki, and in compliance with the
study protocol, International Conference on Harmonisation-Good
Clinical Practice E6 regulations, and applicable regulatory require-
ments. Trial registration: EudraCT 2015-005443-14; NCT02638207.
2.2 | Patient population
The study will enrol a minimum of 140 adult patients with definite or
probable CIDP according to EFNS/PNS criteria1 from approximately
45 study sites worldwide. The enrolment period is expected to last for
about 20 months. Eligible patients will be those who have active dis-
ease (defined below) and are dependent on IVIg or corticosteroids.
Full study inclusion and exclusion criteria are shown in Table 1.
After screening, eligible patients will undergo a predefined reduc-
tion of immunoglobulin or corticosteroids over a maximum of
12 weeks or until deterioration (washout phase). Immunoglobulin
doses will be reduced by 25% at each sequential infusion, and cortico-
steroids will be reduced as per investigator discretion.
Patients with deterioration of CIDP during the washout phase (ie,
those with active disease) will be randomised to receive study treatment.
Deterioration is defined as a decrease in the patients' global impression of
change (PGIC) scale plus one of the following: (1) an increase of ≥1 point
on the adjusted inflammatory neuropathy cause and treatment (INCAT)
disability score,6 (2) a decrease of ≥8 kPa in grip strength in one hand,15 or
(3) an Inflammatory Rasch-built Overall Disability Scale (I-RODS) minimum
clinically important difference SE (MCID-SE) cut-off of −1.96 or less.16,17
Patients who do not experience deterioration of CIDP during the
12-week washout phase (ie, those with inactive disease during the
12 weeks) will not continue in the study. During the study, the investi-
gator may decide to withdraw patients in cases of adverse events
(AEs), poor compliance, withdrawal of patient consent, pregnancy, risk
of severe harm due to continued study treatment or protocol proce-
dures, disease development that interferes with study treatment or
meets an exclusion criterion, or administration of an immunoglobulin
product other than panzyga. Additional patients will be enrolled when
the proportion of patients who withdraw exceeds 10% (unless the
planned number of patients in the dose group has already been
achieved). Replacement patients will be assigned to the same dose
group as the withdrawn patients; however, patients who withdraw
from the study because of safety issues will not be replaced.
2.3 | Study treatment
All patients who worsen in the washout phase will receive an initial
loading dose of IVIg 2.0 g/kg. Patients will then be centrally rando-
mised to maintenance treatment using an interactive web response
system and stratified by previous immunoglobulin or corticosteroid
treatment using a stratified block design. Patients will be assigned in a
1:2:1 ratio to receive double-blind maintenance IVIg (panzyga) doses
of 0.5, 1.0, or 2.0 g/kg, respectively, administered every 3 weeks
(4 days) for 24 weeks (dose-evaluation phase).
To maintain blinding during the dose-evaluation phase, all patients
will receive the same infusion volume as in the 2.0 g/kg treatment
arm, using saline solution to match the volume in the 0.5 and 1.0 g/kg
treatment arms. Each infusion will be administered over 2 consecutive
days, and the content of each infusion bag will be concealed with an
overpouch (normally used for light protection) and new identical labels
on both IVIg and saline bags. The IVIg and saline solutions will not be
mixed prior to administration (ie, no dilution of IVIg will occur).
Rescue medication with 2 doses of IVIg 2.0 g/kg given 3 weeks apart
may be administered to the patients in the IVIg 0.5 and 1.0 g/kg groups if
they have: (1) deterioration of CIDP (defined as an increase in adjusted
INCAT disability score of ≥1 point) after week 3 and before week 18; or
(2) no improvement in CIDP (defined as an unchanged adjusted INCAT dis-
ability score) at week 6. After administration of rescue medication, these
patients discontinue study treatment and attend an end-of-study assess-
ment visit at 3 weeks after the second rescue dose. Patients in the IVIg
2.0 g/kg group with deterioration of CIDP after week 3 and before week
18 or no improvement at week 6 will also discontinue study treatment.
A summary of permitted and prohibited concomitant medications
during the study is shown in Table 2.
2.4 | Study endpoints
The primary efficacy endpoint is the proportion of patients in the IVIg
1.0 g/kg group with response to treatment at week 24 (defined as a
decrease in adjusted INCAT disability score of ≥1 point). The adjusted
INCAT disability score differs from the standard score by exclusion of
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changes in upper limb function from 0 (normal) to 1 (minor symptoms)
or from 1 to 0, as these changes are not considered to be clinically rel-
evant in all patients.3
The following secondary efficacy endpoints will also be assessed: pro-
portion of patients in the IVIg 0.5 and 2.0 g/kg groups vs the IVIg 1.0 g/kg
group with response to treatment at week 24 based on the adjusted
INCAT disability score, grip strength (assessed by Martin Handheld Vigori-
meter, Gebrüder Martin GmbH & Co. KG, Tuttlingen, Germany) using the
MCID cut-off of 8 kPa, and I-RODS score using the MCID-SE cut-off of
−1.96 or less16; the time to first confirmed worsening (ie, increase from
baseline by ≥1 point) in the adjusted INCAT disability score; the time to
improvement (ie, 1 point decrease from baseline) in adjusted INCAT dis-
ability score; the time to first confirmed worsening from baseline in I-
RODS score; the time to decrease in I-RODS score; mean change from
baseline to end-of-study assessment visit in grip strength of both hands, I-
RODS score, Pain Intensity Numeric Rating Scale (PI-NRS), and sum of
the distal evoked amplitude of 4 right-sided and 4 left-sided motor nerves
(peroneal, tibial, ulnar, and median); and the absolute number of improvers
in grip strength and I-RODS during the study.
Exploratory efficacy endpoints will include the mean change from
baseline to study end in Modified Fatigue Severity Scale (FSS), number
of patients with improvement of ≥4 points in Medical Research Council
(MRC) sum score at week 12 or at time of rescue medication, and Short-
Form 36-item (SF-36) health survey physical component score, mental
component score, and their 8 health domains; and the time to decrease
in MRC sum score to baseline (or below) after temporary increase.
Safety endpoints will be assessed throughout the 24-week dose-
evaluation phase and will include the incidence of all AEs; short-term
tolerance parameters, including vital signs; physical and neurological
examination findings; and laboratory parameters (haematology and
clinical chemistry) and tests for viral safety.
The schedule of assessments performed at each study visit is
summarised in Figure 2.
2.5 | Statistical analysis
The statistical analysis will be delegated under an agreement of trans-
fer of responsibilities to an external contract research organisation.
Calculation of the sample size is based on the proportion of
patients with treatment response in the IVIg 1.0 g/kg group. Based
on previous trials,3,7 a threshold of 42% responders was chosen for
the evaluation of the primary endpoint. To achieve a power of
≥80%, a minimum of 62 evaluable patients in the IVIg 1.0 g/kg group
FIGURE 1 Overview of ProCID study design. CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; INCAT, inflammatory
neuropathy cause and treatment; I-RODS, inflammatory Rasch-built overall disability scale; IVIg, intravenous immunoglobulin; MCID-SE, minimum
clinically important difference-SE; PGIC, patient global impression of change
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is needed. Therefore, the study plans to enrol 70 patients in this
group to account for possible dropouts. For the comparison between
doses, half of the eligible patients will be enrolled in the standard
dose group (1.0 g/kg) and the other half in the lower (0.5 g/kg) and
higher (2.0 g/kg) dose groups. The total target enrolment is
140 patients.
Statistical evaluation of the primary and secondary endpoints will
be presented for each randomisation stratum (ie, prior treatment with
IVIg or corticosteroids) separately. No further subgroup analyses are
pre-specified. Further comparisons between CIDP variants may be
added post hoc as indicated by the data.
The statistical analysis will consider the safety set (SAF), full
analysis set (FAS), and per-protocol set (PPS) patient populations
(Table 3). The primary endpoint analysis will be conducted for the
FAS and PPS, the secondary endpoints will be evaluated in the
FAS and in the PPS (in case the 2 populations differ by >5%), and
the safety analysis will be conducted in the SAF. All efficacy and
safety analyses will be summarised using descriptive statistics.
In general, data derivations will be based on observed values only,
and missing data will not be imputed. If missing values occur in the
confirmatory analysis of the FAS primary endpoint, they will be
imputed as worst observed values (ie, observed patients will be ana-
lysed as a non-responder).
3 | DISCUSSION
The ProCID study is a randomised, double-blind, multi-centre, phase
III trial that has been designed to compare 3 different IVIg mainte-
nance doses for the treatment of patients with CIDP: 0.5, 1.0, and
2.0 g/kg once every 3 weeks for 24 weeks. The use of 3 maintenance
TABLE 1 Study inclusion and exclusion criteria
Inclusion criteria
• Age ≥18 years
• A diagnosis of definite or probable CIDP according to the EFNS/PNS
2010 guideline, including patients with MADSAM or pure motor
CIDP
• Currently dependent on immunoglobulin or corticosteroid treatment
• Active disease (ie, not in remission) with progression or relapse prior
to study entry or during the washout phase
• Weakness of at least 2 limbs
• Adjusted INCAT disability score of 2 to 9, with a score of
2 exclusively from leg disability
• Written, fully informed, voluntary consent before conduction of any
study-related procedures
Exclusion criteria
• Unifocal forms of CIDP, pure sensory CIDP or MMN with conduction
block
• Previous failure of immunoglobulin treatment
• Treatment with immunomodulatory or immunosuppressive agents (eg,
ciclosporin, methotrexate, mitoxantrone, mycophenolate mofetil or
azathioprine) within 6 months of study baseline
• Treatment with rituximab, alemtuzumab, cyclophosphamide, or other
intensive chemotherapy, previous lymphoid irradiation or stem cell
transplantation within 12 months of study baseline
• Respiratory impairment requiring mechanical ventilation
• Myelopathy or evidence of CNS demyelination or significant
persisting neurological deficits from stroke or CNS trauma
• Clinical evidence of peripheral neuropathy from another cause such as
connective tissue disease or systemic lupus erythematosus, HIV
infection, hepatitis or Lyme disease, cancer (with the exception of
basal cell skin cancer), or IgM paraproteinaemia with anti-myelin-
associated glycoprotein antibodies
• Diabetic neuropathy, with the exception stable HbA1c (not
exceeding the required normal values) in treated patients with
diabetes
• Body mass index ≥40 kg/m2
• Cardiac insufficiency (NHYA III/IV), cardiomyopathy, significant
cardiac dysrhythmia requiring treatment, or unstable or advanced
ischaemic heart disease
• Severe liver disease (ALT 3× greater than normal) or severe kidney
disease (creatinine levels 1.5× greater than normal)
• Hepatitis B, hepatitis C, or HIV infection
• Thromboembolic events, including a history of DVT within 12 months
of study baseline, any history PE, or susceptibility to DVT or PE
• Uncompensated hypothyroidism (abnormally high TSH and
abnormally low thyroxine) or known vitamin B12 deficiency without
adequate substitution therapy
• Medical conditions that may alter protein catabolism and/or IgG
utilisation (eg, protein-losing enteropathy, nephrotic syndrome)
• Known IgA deficiency with antibodies to IgA
• History of hypersensitivity, anaphylaxis or severe systemic response
to immunoglobulin, blood or plasma-derived products, or any
component of panzyga
• Known blood hyperviscosity or other hypercoagulable states
• Use of other blood or plasma-derived products within 3 months of
study baseline
• Past or present history of drug or alcohol abuse within 5 years of
study baseline
• An inability or unwillingness to understand or comply with the study
protocol
• Participation in another interventional clinical study with an
investigational medicinal product treatment currently or within
3 months of baseline
• Women who are breast feeding, pregnant, planning on becoming
pregnant, or unwilling to use effective birth control during the
study
ALT, alanine aminotransferase; CIDP, chronic inflammatory demyelinat-
ing polyradiculoneuropathy; CNS, central nervous system; DVT, deep
vein thrombosis; EFNS, European Federation of Neurological Societies;
HbA1c, glycated haemoglobin; HIV, human immunodeficiency virus;
IgA/G/M, immunoglobulin A/G/M; INCAT, Inflammatory Neuropathy
Cause and Treatment; MADSAM, multi-focal acquire demyelinating sen-
sory and motor neuropathy; MMN, multi-focal motor neuropathy;
NHYA, New York Heart Association; PE, pulmonary embolism; PNS,
Peripheral Nerve Society; TSH, thyroid-stimulating hormone.
TABLE 2 Summary of permitted and prohibited concomitant
medications
Permitted medications Prohibited medications
• Stable doses of azathioprine
(if receiving for ≥12 months
prior to baseline)
 Azathioprine should be
continued at the same
dosage during study
treatment
• Stable doses of corticosteroids
(prednisolone or equivalent)
≤20 mg/d or equivalent in
patients with prior
corticosteroid therapy
• Paracetamol as needed for
mild pain
• Any other blood or plasma-
derived products (except for
emergency reasons)
• Patients who receive
immunoglobulin preparations
other than panzyga will be
withdrawn from the study
• Corticosteroids (prednisolone
or equivalent) > 20 mg/d or
equivalent
• Plasma exchange
• Ciclosporin, methotrexate,
mitoxantrone, mycophenolate
mofetil, interferon or other
immunosuppressive or
immunomodulatory drugs
• Rituximab, alemtuzumab,
cyclophosphamide, or other
chemotherapeutic regimens
• Any experimental treatment
• Routine pre-medication to
alleviate potential tolerability
issuesa
a Patients who experience 2 consecutive infusion-related adverse events
may receive pre-medication with antipyretics, antihistamines, or antie-
metic agents.
4 CORNBLATH ET AL.
dose groups in the dose-evaluation phase will allow for confirmation
of the clinical efficacy of IVIg observed in previous clinical trials.3–12
In a post hoc analysis of the ICE study, almost half of IVIg
responders showed improvement in adjusted INCAT disability scores
within the first 3 weeks of treatment (ie, after the initial 2.0 g/kg load-
ing dose).18 To be comparable with data from the ICE study,3 the pri-
mary endpoint of the ProCID study will be the proportion of patients
in the IVIg 1.0 g/kg group with response to treatment, as defined by
an improvement from baseline of ≥1 point on the adjusted INCAT dis-
ability score. Consistent with the ICE3 and Privigen Impact on Mobility
and Autonomy (PRIMA)7 studies, the primary endpoint of this study
will be assessed at week 24.
The only other randomised-controlled study to have prospectively
evaluated the efficacy of different IVIg doses observed a dose-response
relationship following a single dose of IVIg 0.25, 1.0 or 2.0 g/kg over
5 days.12 Among 60 patients with CIDP or multi-focal motor neuropathy
who received treatment, high-dose IVIg therapy (2.0 g/kg) was associated
with a higher initial response rate compared with the 0.25 and 1.0 g/kg
doses (response rates of 60% vs 15% and 21%, respectively) at 5 weeks;
24-week data were not presented in this study.12 However, this study
was not randomised and did not include a placebo group.19 In the PATH
study of 172 patients with definite or probable CIDP who received
weekly SCIg 0.2 or 0.4 g/kg or placebo, the proportion of patients who
had a relapse was 19% with SCIg 0.4 g/kg and 33% with SCIg 0.2 g/kg.14
Although the difference in relapse rates between SCIg doses was not sig-
nificant, relapse rates with both SCIg doses were significantly lower than
with placebo (56%; P < .001).14
The ProCID study will also evaluate whether different mainte-
nance doses of IVIg may result in changes in treatment response in
patients with definite or probable CIDP, and whether this efficacy will
differ compared with that observed in the ICE3 and PRIMA7 studies.
While maintenance doses of IVIg vary considerably, most patients
start with a standard maintenance dose of 1 g/kg every 3 weeks (or e-
quivalent), with subsequent dose adjustments being made as needed.
TABLE 3 Definitions of study patient populations
Patient
population Definition
SAF All randomised patients who receive at least part of one
infusion of study treatment
FAS According to the intent-to-treat principle, and includes
all patients from the SAF population for whom data
were collected post-infusion of study treatment
PPS A subset of the FAS, which excludes patients with
significant protocol deviations that could potentially
significantly affect evaluation of the primary outcomea
FAS, full analysis set; PPS, per-protocol set; SAF, safety set.
a The classification of protocol violations will be conducted and documen-
ted before the database is locked, the data is unblinded and the statisti-
cal analyses are performed.
FIGURE 2 Schedule of study visit assessments during the dose-evaluation phase. AEs, adverse events; FSS, fatigue severity scale; INCAT,
inflammatory neuropathy cause and treatment; I-RODS, inflammatory Rasch-built overall disability scale; MRC, Medical Research Council; PGIC,
Patients' global impression of change; PI-NRS, pain intensity numeric rating scale; SF-36, short form 36 items health status
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This study will evaluate whether a higher or lower starting dose to the
maintenance phase is better than the widely used standard dose of
1 g/kg every 3 weeks and will assess the safety and tolerability of
these additional doses to provide clinicians further data in choosing
IVIg maintenance doses for patients with CIDP.
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